Jovana Golijanin
Overview
Explore the profile of Jovana Golijanin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barnes C, Schoofs T, Gnanapragasam P, Golijanin J, Huey-Tubman K, Gruell H, et al.
Sci Adv
. 2022 Aug;
8(32):eabp8155.
PMID: 35960796
The induction of broadly neutralizing antibodies (bNAbs) is a potential strategy for a vaccine against HIV-1. However, most bNAbs exhibit features such as unusually high somatic hypermutation, including insertions and...
2.
Escolano A, Gristick H, Abernathy M, Merkenschlager J, Gautam R, Oliveira T, et al.
Nature
. 2019 May;
570(7762):468-473.
PMID: 31142836
Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal models, suggesting that a vaccine that elicits these antibodies would be protective in humans. However, it has not yet...
3.
Schoofs T, Barnes C, Suh-Toma N, Golijanin J, Schommers P, Gruell H, et al.
Immunity
. 2019 May;
50(6):1513-1529.e9.
PMID: 31126879
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are potential therapeutic agents. We identified SF12 and related bNAbs with up to 62% neutralization breadth from an...
4.
Mayer C, Gazumyan A, Kara E, Gitlin A, Golijanin J, Viant C, et al.
Science
. 2017 Sep;
358(6360).
PMID: 28935768
B cells undergo rapid cell division and affinity maturation in anatomically distinct sites in lymphoid organs called germinal centers (GCs). Homeostasis is maintained in part by B cell apoptosis. However,...
5.
Horwitz J, Bar-On Y, Lu C, Fera D, Lockhart A, Lorenzi J, et al.
Cell
. 2017 Aug;
170(4):637-648.e10.
PMID: 28757252
Non-neutralizing antibodies (nnAbs) to HIV-1 show little measurable activity in prevention or therapy in animal models yet were the only correlate of protection in the RV144 vaccine trial. To investigate...
6.
Robbiani D, Bozzacco L, Keeffe J, Khouri R, Olsen P, Gazumyan A, et al.
Cell
. 2017 May;
169(4):597-609.e11.
PMID: 28475892
Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil and Mexico for...
7.
Nishimura Y, Gautam R, Chun T, Sadjadpour R, Foulds K, Shingai M, et al.
Nature
. 2017 Mar;
543(7646):559-563.
PMID: 28289286
Highly potent and broadly neutralizing anti-HIV-1 antibodies (bNAbs) have been used to prevent and treat lentivirus infections in humanized mice, macaques, and humans. In immunotherapy experiments, administration of bNAbs to...
8.
Freund N, Wang H, Scharf L, Nogueira L, Horwitz J, Bar-On Y, et al.
Sci Transl Med
. 2017 Jan;
9(373).
PMID: 28100831
Some HIV-1-infected patients develop broad and potent HIV-1 neutralizing antibodies (bNAbs) that when passively transferred to mice or macaques can treat or prevent infection. However, bNAbs typically fail to neutralize...
9.
Golijanin J, Amin A, Moshnikova A, Brito J, Tran T, Adochite R, et al.
Proc Natl Acad Sci U S A
. 2016 Oct;
113(42):11829-11834.
PMID: 27688767
Bladder cancer is the fifth most common in incidence and one of the most expensive cancers to treat. Early detection greatly improves the chances of survival and bladder preservation. The...
10.
Gristick H, von Boehmer L, West Jr A, Schamber M, Gazumyan A, Golijanin J, et al.
Nat Struct Mol Biol
. 2016 Sep;
23(10):906-915.
PMID: 27617431
HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env). Variability in high-mannose and...